Business Context and Reporting Period
This Form 8-K is a current report filed by Cerecor Inc. (not Avalo Therapeutics, Inc.) on June 21, 2021, regarding events occurring on June 15, 2021. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CERC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Board Resignation: Sol Barer resigned from the Board of Directors effective June 15, 2021. The resignation was not related to any disagreement with the Company regarding operations, policies, or practices.
- Advisory Role: Dr. Barer will serve as a special advisor to the Board and the Company for at least one year, including a seat on the Strategic Advisory Board.
- Board Appointments: Following the resignation, Michael Cola (Chief Executive Officer) was appointed Chairman of the Board, and Dr. Suzanne Bruhn was appointed Lead Independent Director.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document is limited to the disclosure of officer and director changes under Item 5.02.
Investor Verification Checklist
- Verify the effective date of Sol Barer's resignation (June 15, 2021).
- Confirm the new leadership structure: Michael Cola as Chairman and Dr. Suzanne Bruhn as Lead Independent Director.
- Review the terms of Dr. Barer's new role as a special advisor and member of the Strategic Advisory Board.
- Check subsequent filings for any financial impact related to these governance changes.